KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 83 filers reported holding KEROS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,755,760 | -29.6% | 902,000 | -11.2% | 0.00% | 0.0% |
| Q2 2023 | $40,818,983 | +1.2% | 1,015,903 | +7.6% | 0.00% | 0.0% |
| Q1 2023 | $40,315,531 | -56.6% | 944,159 | -51.2% | 0.00% | -33.3% |
| Q4 2022 | $92,979,974 | +164.8% | 1,936,276 | +107.4% | 0.00% | +50.0% |
| Q3 2022 | $35,119,000 | +28.3% | 933,512 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $27,374,000 | -26.4% | 990,752 | +44.9% | 0.00% | 0.0% |
| Q1 2022 | $37,177,000 | -3.0% | 683,647 | +4.4% | 0.00% | 0.0% |
| Q4 2021 | $38,324,000 | +43.0% | 654,992 | -3.3% | 0.00% | +100.0% |
| Q3 2021 | $26,793,000 | -7.1% | 677,268 | -0.3% | 0.00% | -50.0% |
| Q2 2021 | $28,836,000 | -35.3% | 678,978 | -6.2% | 0.00% | -33.3% |
| Q1 2021 | $44,551,000 | +48.2% | 723,823 | +69.9% | 0.00% | +50.0% |
| Q4 2020 | $30,056,000 | +685.4% | 426,091 | +329.4% | 0.00% | – |
| Q3 2020 | $3,827,000 | +20.0% | 99,226 | +16.7% | 0.00% | – |
| Q2 2020 | $3,189,000 | – | 85,011 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |